A PhaseⅠ Comparative Study to Evaluate the Pharmacokinetics of QL2108 to Dupixent®

NCT06614907 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

198

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: QL2108 injection
DRUG: Dupixent®

Sponsor

Qilu Pharmaceutical Co., Ltd.